"We were granted three patents from the United States Patent and Trademark Office with numerous patents pending, which demonstrates a strong product pipeline."
Nice job BioPharmX! Now bring on the Big News we've all been waiting for!!
Cash and cash equivalents as of January 31, 2018, were $7.6 million. Additionally, BioPharmX reported that after the end of the year and through the date of this press release, the company received $7.0 million in cash through warrant exercises subsequent to January 31, 2018.
If Warrant Holders have faith/exercising, I have faith!
Market Data 
Markets 
AI
